Agger EM[Author] - Search Results

Year	Number of Results
2000	2
2001	2
2002	2
2003	2
2004	1
2005	3
2006	3
2007	5
2008	10
2009	13
2010	12
2011	13
2012	6
2013	7
2014	9
2015	5
2016	8
2017	7
2018	2
2019	3
2020	1
2024	0

1

The Memory Immune Response to Tuberculosis.

Kirman JR, Henao-Tamayo MI, Agger EM. Kirman JR, et al. Among authors: agger em. Microbiol Spectr. 2016 Dec;4(6). doi: 10.1128/microbiolspec.TBTB2-0009-2016. Microbiol Spectr. 2016. PMID: 28087940 Free article. Review.

2

Cationic liposomes as vaccine adjuvants.

Christensen D, Korsholm KS, Andersen P, Agger EM. Christensen D, et al. Among authors: agger em. Expert Rev Vaccines. 2011 Apr;10(4):513-21. doi: 10.1586/erv.11.17. Expert Rev Vaccines. 2011. PMID: 21506648 Review.

3

Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.

Agger EM. Agger EM. Adv Drug Deliv Rev. 2016 Jul 1;102:73-82. doi: 10.1016/j.addr.2015.11.012. Epub 2015 Nov 17. Adv Drug Deliv Rev. 2016. PMID: 26596558 Free PMC article. Review.

4

Cationic liposomes as vaccine adjuvants.

Christensen D, Korsholm KS, Rosenkrands I, Lindenstrøm T, Andersen P, Agger EM. Christensen D, et al. Among authors: agger em. Expert Rev Vaccines. 2007 Oct;6(5):785-96. doi: 10.1586/14760584.6.5.785. Expert Rev Vaccines. 2007. PMID: 17931158 Review.

5

Antigen discovery and tuberculosis vaccine development in the post-genomic era.

Louise R, Skjøt V, Agger EM, Andersen P. Louise R, et al. Among authors: agger em. Scand J Infect Dis. 2001;33(9):643-7. doi: 10.1080/00365540110026971. Scand J Infect Dis. 2001. PMID: 11669220 Review.

6

Liposome-based cationic adjuvant formulations (CAF): past, present, and future.

Christensen D, Agger EM, Andreasen LV, Kirby D, Andersen P, Perrie Y. Christensen D, et al. Among authors: agger em. J Liposome Res. 2009;19(1):2-11. doi: 10.1080/08982100902726820. J Liposome Res. 2009. PMID: 19515003 Review.

7

A novel TB vaccine; towards a strategy based on our understanding of BCG failure.

Agger EM, Andersen P. Agger EM, et al. Vaccine. 2002 Nov 22;21(1-2):7-14. doi: 10.1016/s0264-410x(02)00447-4. Vaccine. 2002. PMID: 12443657 Review.

8

License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems.

Foged C, Hansen J, Agger EM. Foged C, et al. Among authors: agger em. Eur J Pharm Sci. 2012 Mar 12;45(4):482-91. doi: 10.1016/j.ejps.2011.08.016. Epub 2011 Aug 25. Eur J Pharm Sci. 2012. PMID: 21888971 Review.

9

High Antigen Dose Is Detrimental to Post-Exposure Vaccine Protection against Tuberculosis.

Billeskov R, Lindenstrøm T, Woodworth J, Vilaplana C, Cardona PJ, Cassidy JP, Mortensen R, Agger EM, Andersen P. Billeskov R, et al. Among authors: agger em. Front Immunol. 2018 Jan 15;8:1973. doi: 10.3389/fimmu.2017.01973. eCollection 2017. Front Immunol. 2018. PMID: 29379507 Free PMC article.

10

Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice.

Mortensen R, Clemmensen HS, Woodworth JS, Therkelsen ML, Mustafa T, Tonby K, Jenum S, Agger EM, Dyrhol-Riise AM, Andersen P. Mortensen R, et al. Among authors: agger em. Commun Biol. 2019 Aug 5;2:288. doi: 10.1038/s42003-019-0530-3. eCollection 2019. Commun Biol. 2019. PMID: 31396568 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

98 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year